Skip to main content
. 2011 May 10;3:69–82. doi: 10.2147/OAJU.S7230

Figure 3.

Figure 3

Phase II design.

Notes: *Placebo patients who progressed could cross over to sorafenib; **Including 36 patients without bidimentional tumor measurements, but with radiological evidence of progression.

Copyright © 2011, Forum Service. Reproduced with permission from Porta and Bracarda.31